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adrenergic (sympathetic) and cholinergic (parasympathetic)
systems determines airway calibre. Both types of receptors
are also involved in the regulation of bronchial and alveolar
mucus secretion (1â€”3).
Changes in the number or the properties of these receptors
may play a role in asthma and chronic obstructive pulmo
nary disease (COPD). Medicamentous treatment may also
lead to changed characteristics of these binding sites. For
example, patients suffering from asthma and COPD are
often treated with @32-adrenoceptoragomsts (sympathomimet
ics) and muscarinic antagonists (parasympatholytics).
Chronic exposure of tissues to these drugs can lead to
rebound effects after cessation of therapy and to a phenom
enon known as tolerance, which is a reduction in the
sensitivity of the tissue to the drug, accomplished by
uncoupling, internalization or downregulation of the recep
tors (4â€”10).
PET offers a unique possibility to study the muscarinic
and f3-adrenergic receptors in vivo. Consequently, it may
become clear whether there are differences in receptor
densities between the lungs of patients suffering from
asthma or COPD and healthy volunteers. Also the effects at
the receptor level after chronic treatment of these patients
with long- and short-acting @3-sympathomimeticsand para
sympatholytics can be studied.
Pulmonary @3-adrenergicreceptor densities have been
determined with PET in asthmatics and age-matched healthy
volunteers after intravenous administration of 4-(3-t-
butylamino-2-hydroxypropoxy)-benzimidazol-2[' 1C]-one
([â€˜1C]CGP12177).Nodifferencescouldbefoundbetween
both groups indicating the absence of a primary @3-adrener
gic deficit in asthma (11), although it should be noted that
[â€œC]CGP12177bindsprimarilyto thealveolar eceptors
(for >90%). These receptors are not believed to be involved
in the pathophysiology of asthma. Because only a fraction of
the binding occurs to receptors on the smooth muscle cells in the
airways (<10%), it may not be possible to detect changes in
this population. Also, the effect of long-term @32-adrenergic
agonist dosing on pulmonary receptor density was studied.
After salbutamol treatment, @3-adrenoceptordensity de
creased on average by 22% (P < 0.05) in human lungs
(12,13).
Because the cholinergic nervous system is the dominant
The characterizationof pulmonarymuscannicreceptorswith
PET is still in its infancy. Because approximately 70% ofthe lungs
consistsof air andpulmonarymuscarinicreceptordensitiesare




002) was developed. We administered this radioligand to four
healthyhumanvolunteersto examineitssuitabilityforstudying
pulmonarymuscannicreceptorsinvivo.Methods: [11C]VC-002
(185 MBq,specificactMty > 7.4 TBq/mmol)was intravenously
injectedon 2 separatedays, with an intervalof at least 1 wk. On
the first day the volunteerswere not pretreated,but on the
secondday they receivedthe anticholinergicglycopyrronium
bromide (Robinul; 2 x 0.1 mg intravenous) 25 and 30 mm
beforethe injectionof the radiopharmaceutical.CE1@O]Oscans
(approximately740 MBq[20 mCi]by inhalation)were acquired
beforethe receptorscanto calculatepulmonarybloodvolume.
Results:OnPETimagesofthethorax,thelungswereclearly
visible. After the volunteer was pretreated with glycopyrronium
bromide, pulmonary uptake of the radioligand was reduced to
32%Â±12%ofthecontrolvalueat60mmpostinjectiona dthe
lungscould no longerbe seen. (R)-[11C]-VC-002was rapidly
clearedfromplasmaandwasslowlymetabolized uringthetime
course (60 mm) of the PET scan. The fraction of radioiigand
representing parent compound decreased from 99.9% at the
timeof injectionto 82% at 40â€”60mmpostinjection,bothin the
presenceand absenceof Robinul.Pulmonarytissue-to-plasma
ratios,calculatedon a count-per-minute-per-grambasis,reached
a plateau value of 17.8 Â±1.2 at 40â€”50mm postinjection.




he autonomic nervous system regulates the contraction
and relaxation of the smooth muscle cells in the airways.
Binding of noradrenaline to @3-adrenergicreceptors causes
relaxation, whereas the binding of acetylcholine to musca
rinic receptors causes contraction. The balance between the
ReceivedJul.27,1998;revisionacceptedFeb.4, 1999.
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soda lime trap, the C['50]O was passed into a chemical processing
box (Scanditronix,Uppsala,Sweden). Qualitycontrolconsisted of
radio-gas chromatography analysis of a sample of C['50]O oh
tamed from a test run, performed immediately before the actual
radiosynthesis. To avoid bacteriological contamination, the C['5O]O
was transferred to the mouth by a 0.22-pm filter. The total amount
of nonradioactiveCO administeredis such (<90 pmol) thatit does
not produce any physiological effect and may be considered
nontoxic (<0.25% of total hemoglobin occupied).
HumanVolunteers
The participants were recruited according to the following
criteria: age 18â€”50y, prebronchodilator forced expiratory volume
in one second (FEy,) > 80% of predicted, nonsmoker or cx
smoker (smoking terminated for >1 y). Excluded were people with
a positive history regardingwheezing and tightness of the chest,
angina pectoris, myocardial infarct or stroke, presence of pulmo
nary diseases including asthma, open angle glaucoma, pyloric
obstruction, obstruction of the neck of the urinary bladder, obstruc
tion of the intestine,severe renal,hepaticor cardiovasculardisease
or atopy (at least one positive reaction to known allergens in
intracutaneous skin tests). Also excluded were people who used
@3-mimetics( albutamol) and theophylline (S12 and 48 h, respec
tively) before the study, people with a diastolic blood pressure
persistently >100 mm Hg and women who were pregnant.
All volunteers underwent the following screening: anamnesis,
physical examination, routine blood biochemistry to assess kidney
and liver function, electrocardiogram,skin tests for allergic rear
tions and pulmonary function tests (spirometry, bronchial hyperac
tivity). Airway responsiveness to methacholine was determined
using the 2-mm tidal breathing method (23,24). The provocation
concentration to achieve a 20% decrease in FEV, had to be >8
mg/mL. The study was approved by the Medical Ethics Committee
of the Groningen University Hospital. Each subject was informed
both orally and in writing about the purpose and risks of the
experiment and gave informed consent.
StudyProtocol
At the beginning of the study, a venous cannula was placed in
one of the veins of one of the forearms.Afterpatencyof the ulnary
arterywas proven by the Allen test (25), an arterialcannula was
placed in the radial artery of the contralateralarm under local
anesthesia with lidocain. The venous cannula was used for
injection and the arterial line for blood sampling. Subsequently, the
volunteer was placed into the PET camera (full width at half
maximum = 6 mm, axial field of view of 10.8 cm, images
reconstructed in 31 transaxial planes) (Siemens ECAT 951/31;
Siemens Medical Imaging, Knoxville, TN). A rectilinear scan was
obtained for proper positioning (carmnaat the center of the field of
view). Then a transmission scan was obtained, using the internal
@Ge/@Oasources, to correct for attenuation. Subsequently, approxi
mately 740 MBq (20 mCi) C['5O]O were administered as a bolus
by inhalation.Cameraacquisition startedat complete expiration
and proceeded over an interval of 10 rain (10 time frames of I mm)
to acquire informationon the size of the pulmonaryblood pool.
During the C['50]O scan, arterial blood samples (1.5 mL) were
drawn at 2.5, 5 and 7.5 mm after the onset of data acquisition.
These blood samples were then counted in a gamma counterthat
was cross calibratedwith the PET camera. Finally, 185 MBq (5
mCi) (R)-[â€•C]-VC-002were administeredto the volunteer and
arterial blood samples (2 mL) were drawn at 0.5-mm intervals
bronchoconstrictor neural pathway in the human airways, it
is reasonable to presume that this system may play a role in
the pathophysiology ofasthma and COPD. Increased musca
rinic cholinergic activity may occur through an increase in
receptor density or affinity or through an increase in the
efficacy of receptor/signal transduction coupling. Studies of
the binding of [3H]quinucidinyl benzilate ([3H]QNB) to
human lung tissue from healthy subjects and patients with
chronic obstructive lung disease showed no differences in
binding affinity (KD) but an unexpectedly low number of
muscarimc receptors in the patient group (83 and 26
fmol/mg protein for normals and patients, respectively) (14).
In another study, no significant differences were found in
either the KD or receptor concentration between the healthy
subject and patient groups (15,16). A possible defect in the
feedback inhibitory M2 receptor was reported in patients
suffering from asthma (17,18).
Although the potent muscariic antagonist [â€œCimethyl
quinuclidinyl benzilate ([â€œC]MQNB)has been used exten
sively for the visualization/quantification of muscariic
receptors in the heart by PET (19â€”21),to our knowledge no
attention has been paid to the in vivo characterization of
pulmonary muscarinic receptors by means of this imaging
technique.
During animal experiments in our laboratory, it became
clear that N-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy
2-phenylacetate methiodide ([R]-VC-002) is a suitable can
didate for the evaluation of pulmonary muscarimc receptors
(22). This study reports the results of the first human studies




(R)-[' â€˜C]-VC-002was synthesized by quaternization of
N-methyl-pipendin-4-yI 2-cyclohexyl-2-hydroxy-2-phenylacetate
with [â€œC]CH3I(22). The product was purified by high-perfor
mance liquid chromatography (HPLC) (10 pm) (CN-RadPak;
Waters, Milford, MA). Mobile phase: H20 (1% NH.IOH [20%],
acidified to pH 4.5 with acetic acid): CH3CN 68:932, v/v,
running at 4 mLlmin. The retention time of the product was 9 mm,
and the chemical and radiochemicalpuritywas >99%. The total
synthesis time was 40 mm, and the radiochemical yield varied
between 40% and 60% (corrected for decay). The specific activity
was always higher than 7.4 TBq/mmol at the time of injection.
After evaporationof the solvents, the radioligandwas dissolved in
8 mL phosphate-buffered saline (140 mmoIIL NaCl; 9.0 mmol/L
Na3PO4;1.3 mmol/L NaH2PO4).Before injection, the solution was
filtered (0.22-pm Millex GP filter; Millipore, Danvers, MA) into an
evacuated stervial. The solution was colorless, isotonic, sterile and
apyrogenic, and the pH was 6.5â€”7.5.(R)-[â€•C}-VC-002passed the
test on â€œacutetoxicityâ€•(European Pharmacopoeia; Dutch Phanna
copoeia, 9th ed.) at a 10,000-fold higher dose than was adminis
teredto humansperkilogramof body weight.
C['50]O was synthesized from [â€˜@O]-O2produced by our
cyclotron by the â€˜4N[d,n]'50nuclearreaction. The [â€˜@O]-O2was led
through a column containing charcoal at 900Â°C,transformingit
into C['5O]O.After removal of traceSof C['50]02 by means of a
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during the initial 5 ruin and at 10-mm intervalsfrom 10 to 60 mm
postinjection.PEr imageswereacquiredovera periodof 60 mm.The
followingtime frames were used: 8 frames of 15 s were followedby 4
framesof30s,4framesoflmin,4framesof2min,6framesof4min
and 2 frames of 10 mm.
On theseconddayof thestudy(at least1wk later),an identical
protocol was performed with the following modification: two
lOOjig doses of glycopyrronium bromide (total = 0.2 mg)
(Robimul; Wyeth laboratoria b.v., Hoofddorp, The Netherlands)
were administered by intravenous injection 30 and 25 mm before
injection of the radioligand.
MetaboliteAnalysisandPlasmaProteinBinding
For the determinationof the concentrationof (R)-[â€•C]-VC-002
and labeled metabolites in plasma, arterial blood samples were
drawn at the following time points: 1, 2, 5, 10, 40 and 60 mm
postinjection. Plasma and red blood cells were separated by
centrifugation (2 mm, Hettich centrifuge, EBA ifi; Tuttlingen,
Germany). Subsequently, the plasma samples were treated with
two volumes of CH3CN and spiked with nonlabeled (R)-VC-002.
Then the samples were subjected to HPLC (stationary phase:
Waters C,8 RadPak radial compression module column, 5 pm;
mobile phase: CH3CN:NaH2PO4[50 mmollL]:diethylamine =
50:50:1, pH = 6, flow rate 2.0 mLlmin). Fractions (1 mL) of the
eluate were collected during 15 mm and counted in a calibrated
gamma counter (Compugamma 1282 CS; LKB-Wallac, Turku,
Finland). The recovery from the column exceeded 92%.
Blood samples (1 mL) for the determination ofplasma clearance
were drawn at time intervals of 0.5, 1, 1.5,2, 2.5, 3, 3.5,4, 4.5, 5, 10,
20, 30, 40, 50 and 60 mm after administrationofthe radioligand.After
centrifugationto separateplasmafromblood cells, plasmasamples
(0.25 mL) were counted in the gamma counter.
FIGURE1. PET imagesof muscarinic
receptorsin lungsof female(AandB)and
male(C andD) healthyvolunteersacquired
with (R)-[11C]-VC-002without(Aand C) and
withreceptorblocking(BandD).Transaxial
cross-sections in time frames 24â€”60mm
postinjectionareshown.Notehighuptake
in mammae of female volunteer.
Data Analysis
On the transmission scan, the lungs were clearly visible.
Regions of interest (ROIs) were drawn on left and right lungs using
the transmissionscan. Hilarstructureswere avoided.Subsequently,
the ROIs were projected on the original dynamic emission scan.
Them,time-activity curves for the different ROIs were generated
using ECAT software (version 6.5D) running on a SUN/SPARC
workstation (Sum MicroSystems, Mountain View, CA). Because
data from different studies had to be compared, values of tissue
uptake were normalized to an injected radioactivity of 185 MBq (5
mCi). The time-activity data were analyzed using a nonlinear
regression data analysis program (Enzfit [Elsevier Biosoft, Cam
bridge, UK], Multifit [Johannes Proost, University of Groningen,
The Netherlands]).The fractionof radioactivityin the pulmonary
vascular compartment in the ROIs was calculated with the help of




In these experiments, (R)-[â€•C]-VC-002 was administered
to four healthy volunteers (three men, one woman; agerange
20â€”26y, meanage 32 Â±13y) to assessradioliganduptake
in the lungs before and after intravenous injection of a
standard dose of glycopyrronium bromide (Robinul). Each
volunteer was scanned twice, first with no pretreatment and
then with glycopyrronium bromide.
In Figure 1, four PET images are shown. Figures 1A and
B show the uptake of (R)-[â€•C]-VC-002 in the thorax of a
female volunteer, with (B) and without glycopyrronium
bromide pretreatment (A). In Figures 1C and D, the lungs of
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Metabolism
Metabolism of (R)-[@C]-VC-002 was slow. The fraction
of unmetabolized radioligand in human plasma decreased
from >99% at time zero to approximately 82% at 60 mm
postinjection of the radioligand. Glycopyrronium bromide




In Figure 6, pulmonary tissue-to-plasma ratios calculated
on a count-per-minute-per-gram basis are depicted. These
ratios gradually rise to a plateau value of 17.8 Â±1.2, which
is reached at 40â€”50mm postinjectiom. Blood-to-plasma
ratios were also calculated. These were rather constant
(mean 0.72 Â±0.08) during the time course of the PET study.
DISCUSSION
(R)-[â€•C}-VC-002 meets all the criteria necessary for the
determination of muscarinic receptor densities in human
lungs by means of a multiple injection protocol. The
radioligand is rapidly cleared from plasma (Fig. 4) and is
slowly metabolized in the time period necessary for the PET
scan (Fig. 5). Therefore, the input of radioligand to the
tissues can be accurately determined. Moreover, the blood
concentration of the radioligand can be used as an input
function because whole blood-to-plasma ratios are constant
(mean 0.72 Â±0.08) during the PET study. It may therefore
be possible to estimate the input of (R)-[â€•C]-VC-002 to the
lungs from an ROl placed over the blood pool in the right
ventricularcavity.This was not done in this study because
the canna was at the center of the field of view and the heart
was therefore outside the field of view of the PET camera. In
future studies, arterial blood sampling may be avoided by
the use of blood-pool data as an input function.
a male volunteer are shown with (D) and without glycopyr
ronium bromide pretreatment (C). Peripheral lungs are
clearly visible in the control studies (A and C) but after
intravenous injection of glycopyrromum bromide, the lungs
could no longer be seen (B and D). In these studies, the large
airways can hardly be distinguished. In the female volunteer,
remarkably high uptake was observed at the level of the
mammae.
Kineticsof (RW1C]-VC-002in Lungs
(R)-[â€•C]-VC-002binds to muscariic receptorswithina
few minutes, resulting in an almost constant level of
radioactivity in lungs from 10 to 60 mm postinjection (Fig.
2).Afterglycopyrroniumbromidepretreatment,the levelof
radioactivity in the lungs of the male volunteers was
significantly reduced to 32% Â±12% of the control value at
60 mm (Fig. 3). Glycopyrronium bromide caused a more
rapid washout of radioactivity from lung tissue. From the
C['5O]O scan, the fraction of radioactivity that originated
from pulmonary blood was calculated. In the control study,
on average 2%â€”4%of the radioactivity in the ROl was
localized in pulmonary blood 30-60 miii after injection of
the radioligand (Fig. 2). In the glycopyrronium bromide
study, the fraction of radioactivity in pulmonary blood
corresponded to 8%â€”19%of total radioactivity in the ROl.
Clearanceof RadioactivityfromPlasma
After injection of (R)-[â€•C]-VC-002, plasma radioactivity
decreasedrapidly(Fig.4). In thecontrolstudy,radioactivity
decreased to 5.5% of the peak value within 10 mm;
thereafter, the clearance was much slower (to 1.1% of the
peak value after 60 mm). Although the clearance of radioac
tivity from plasma after pretreatment of the volunteer with
glycopyrronium bromide was less rapid than that in the
control study for each individual, due to large interindividual
variability the difference between control and treated groups








â€”0â€” Total activity in ROl (control
. Total activity in ROi (robinui
â€”a-- Blood activity in ROl (control
A Blood activity in ROl (robinul
FIGURE2. Time-activitycurvesgener-.
ated from AOl in lungsof healthyvolun
teers. Blood volume normalized blood
curves for control and glycopyrronlumbro
mide studiesare also shown.At 50 mm,
totalactivityin AOl is 4.29x 10@cpm/mL,
activityin blood in same AOl is 0.15 x 10@
cpm/mL(controlstudies).
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mide pretreatment(data not correctedfor
blood contribution and expressed as per
centageof control).
Because the number of muscarinic receptors decreases
with the size ofthe airways, with 10 times higher densities in
trachea than in peripheral lungs (26,27), the highest uptake
of radioligand was expected in the large airways. Therefore,
the volunteer was positioned in the PET camera with the
carina in the center of the field of view. Although in PET
images of the thorax the lungs were clearly visible, the
trachea and the main bronchi were hard to distinguish. This
may be due to partial-volume effects since these receptors
are located in a small volume of smooth muscle. A camera
with higher resolution/sensitivity may therefore improve the
PET images. PET images of the thorax of the female
volunteer showed high uptake at the level of the mammae.
Because tracer uptake could be blocked by glycopyrronium
bromide, the elevated uptake may be caused by the interac
tion with muscariic receptors on the secretory or myoepithe





The pulmonary uptake of radioactivity was significantly
reduced (with 68% Â± 12% at 60 miii postinjection) by
treating the volunteers with glycopyrronium bromide. This
indicates that the pulmonary uptake of the radioligand is
largely receptor mediated. To limit the risks to an acceptable
minimum, all participants received only a low dose of
glycopyrronium bromide. No significant effects of the
anticholinergic drug on the heart rate could be detected
during the PET study, in part because glycopyrromum
bromide displays selectivity for the M, and M3 muscariic
receptor subtypes (33). In human heart, the majority of
muscariic receptors are of the M2 subtype (26). Because
blockade of the muscariic receptors by glycopyrroium
bromide is not complete, the amount of nonspecific binding
is hard to determine from this study. From a biexponential
curve fit in Figure 3, it is clear that the percentage of
blockade becomes greater at greater intervals postinjection
1274 THEJoui@&i.OFNUCLEARMEDICINEâ€¢Vol.40 â€¢No. 8 â€¢August1999
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In lungs the apparent off-rate of the radioligand from the
receptor was slow (control study). Although this could be
interpreted as irreversible binding of the radioligand to the
receptors, for [â€œC]MQNB it was calculated that after
dissociation from cardiac muscariic receptors, the probabil
ity of rebinding is much higher than the probability of
diffusing into capillary blood (21). Thus, the apparent
off-rate in a PET study is much slower than the real
dissociation of the ligand/receptor complex.
By performing a C['50]O scan before the injection of the
radioligand, pulmonary blood volume as well as the fraction
of radioactivity in the pulmonary vascular compartment in
the ROIs could be calculated. In the time frames 30-60 mm,
only 2%-4% of the radioactivity in the ROl originated
from pulmonaiy blood, indicating that nearly all the radioac
tivity is located in pulmonary tissue. After glycopyrroium
bromide pretreatment, the fraction of radioactivity in the
vascular compartment corresponded to 8%â€”19%of total
radioactivity in the ROI.
CONCLUSION
(R)-[â€•C]-VC-002is the first radioligand to visualize
pulmonary muscariic receptors in human volunteers. (R)
[â€œC]-VC-002 has favorable in vivo properties and the
synthesis of this radioligand is relatively simple and very
reliable. Because this radiopharmaceutical can be produced
in high yield and with high specific activity, it has consider
able potential for the quantification of pulmonary musca
nc receptors in humans to detect changes induced by
disease, age or treatment.
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FIGURE5. Metabolismof (R)-[11C]-VC-002in humanvolun
teers, fraction of plasma radioactMty representingparent com
poundis expressedas meanÂ±SEMof controlandglycopyrro
niumbromidestudy (solid line Isbiexponentialcurvefit).
(extrapolated to 120 mm, block is 77%). Studies of rats
pretreated with saturating doses of atropine before the
injection of the radioligand (22) showed that nonspecific
binding in the target organs such as lungs and heart is low
(i.e., 10.7% and 0.9% of total tissue uptake, respectively).
That complete blockade was not reached under our experi
mental conditions can also be deduced from Figure 6. In the
glycopyrronium bromide-blocked situation, the increase of
the tissue plasma ratio to a plateau level of 4.7 Â±1.0, which
is reached at 45â€”55mm postinjection, suggests that only
approximately 74% of all muscarmnic receptors in human









ratios after injection of (R)-[11C]-VC-002,
with and without glycopyrronium bromide
pretreatment(meanÂ±SEM),calculatedon
count-per-minute-per-grambasis(notcount
per minute per milliliter).
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